Early Pregnancy Clinical Trial
Official title:
Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion in Young Pregnancy - A Prospective Randomized Controlled Trial.
Verified date | November 2022 |
Source | HaEmek Medical Center, Israel |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Medical termination of pregnancy is a common and safe alternative to surgical termination of pregnancy(8). The current protocol in the investigators unit includes oral administration of Mifepristone 600 mg and oral Misoprostol 400 mcg in a time interval of 48 hours. There is little data to compare the efficacy of concomitant administration of both drugs and different time intervals. This study evaluates the success rate and side effects of medical termination of pregnancy while both drugs are administrated concomitantly in comparison to interval of 48 hours between the drugs.
Status | Active, not recruiting |
Enrollment | 250 |
Est. completion date | December 30, 2023 |
Est. primary completion date | December 30, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - intrauterine singleton pregnancy of less than 49 days, reassured by ultrasound examination - patient who desire to terminate their pregnancy and have approval of the committee for termination of pregnancy - patient who gave their consent to have a surgical abortion eventual if needed Exclusion Criteria: - contraindication to Mifepristone or Misoprostol - suspected ectopic pregnancy - systemic treatment with steroids - adrenal insufficiency - heart and blood vessels disease - coagulopathy or use of anti-thrombotic agents - uncontrolled asthma - liver or kidney insufficiency - anorexia - intrauterine device - breastfeeding |
Country | Name | City | State |
---|---|---|---|
Israel | HaEmek medical center | Afula |
Lead Sponsor | Collaborator |
---|---|
HaEmek Medical Center, Israel |
Israel,
Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA; MOD Study Trial Group. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004 May;103(5 Pt 1):851-9. doi: 10.1097/01.AOG.0000124271. — View Citation
Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA; Medical Abortion at the Same Time (MAST) Study Trial Group. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol. 2007 Apr;109(4):885-94. doi: 10.1097/01.AOG.0000258298.35143.d2. — View Citation
Creinin MD, Schwartz JL, Pymar HC, Fink W. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. BJOG. 2001 May;108(5):469-73. doi: 10.1111/j.1471-0528.2001.00117.x. — View Citation
Garg G, Takkar N, Sehgal A. Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions. J Obstet Gynaecol India. 2015 Apr;65(2):111-6. doi: 10.1007/s13224-014-0605-5. Epub 2014 Oct 31. — View Citation
Goel A, Mittal S, Taneja BK, Singal N, Attri S. Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Arch Gynecol Obstet. 2011 Jun;283(6):1409-13. doi: 10.1007/s00404-011-1881-2. Ep — View Citation
McKinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod. 1993 Sep;8(9):1502-5. doi: 10.1093/oxfordjournals.humrep.a138287. — View Citation
Murthy AS, Creinin MD, Harwood B, Schreiber C. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. Contraception. 2005 May;71(5):333-6. doi: 10.1016/j.contraception.2004.10.006. — View Citation
Schaff E. Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. Contraception. 2006 Jul;74(1):42-4. doi: 10.1016/j.contraception.2006.03.014. Epub 2006 May 12. — View Citation
Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 2001 Aug;64(2):81-5. doi: 10.1016/s0010-7824(01)00229-3. — View Citation
Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. BMJ. 1993 Aug 28;307(6903):532-7. doi: 10.1136/bmj.307.6903.532. — View Citation
von Hertzen H, Piaggio G, Wojdyla D, Marions L, My Huong NT, Tang OS, Fang AH, Wu SC, Kalmar L, Mittal S, Erdenetungalag R, Horga M, Pretnar-Darovec A, Kapamadzija A, Dickson K, Anh ND, Tai NV, Tuyet HT, Peregoudov A; WHO Research Group on Post-ovulatory — View Citation
Wedisinghe L, Elsandabesee D. Flexible mifepristone and misoprostol administration interval for first-trimester medical termination. Contraception. 2010 Apr;81(4):269-74. doi: 10.1016/j.contraception.2009.09.007. Epub 2009 Oct 29. — View Citation
World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation; Special Programme of Research, Development and Research Training; World Health Organisation. Comparison of two doses of mifepristone in combination with misoprostol fo — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Success rate of complete abortion | Success rate of complete abortion without any other surgical intervention | two weeks | |
Secondary | Bleeding amount | Assessment of bleeding amount and duration by the patient (maximum amount of pads per day) and Hemoglobin level before and two weeks after the procedure | two weeks | |
Secondary | Self reported pain intensity after two weeks | Visual analogue scale pain severity with scale from 0 to 10, with score 10 representing the maximum level of pain during those two weeks. | two weeks | |
Secondary | patient's satisfaction | Post operative women's satisfaction with scale from 0 to 10, with score 10 representing the maximum level of satisfaction. the patient will be asked if she will select this method next time if necessary | two weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01639989 -
Doppler Assesment of Blood Flow in the Spiral Arteries
|
N/A | |
Recruiting |
NCT06002412 -
Quality Control of Ultrasound Images During Early Pregnancy Via AI
|
||
Completed |
NCT03258385 -
Vitamin B12 Supplementation to Improve B12 Status and Child Development
|
N/A | |
Completed |
NCT04152278 -
Chlamydia Tracomatis and Other Lower Genital Tract Infections Among Women With Unexplained Early Miscarriage
|
||
Completed |
NCT03161873 -
Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)
|
||
Completed |
NCT02979834 -
When Will I Feel The First Movements of My Baby?
|
N/A | |
Terminated |
NCT02847910 -
ClinicaI Observation of Induced Abortion With Disposable Tissue Suction Tube
|
N/A | |
Completed |
NCT04371991 -
Kisspeptin Levels in Early Pregnancy
|
||
Active, not recruiting |
NCT05142020 -
Biomarkers for Early Screening of Gestational Diabetes Mellitus
|
||
Recruiting |
NCT04717661 -
A Diagnostic Test Study of Characteristic Sound Waves in Radial Artery of Early Pregnant Women
|
||
Completed |
NCT05484869 -
Very Advanced Maternal Aged Pregnants and Early Adolescent Pregnant Women
|
||
Recruiting |
NCT04738370 -
Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy
|
||
Completed |
NCT06228118 -
Clinical Trail of the Lay User Study and Method Comparison Study of Human Chorionic Gonadotropin (HCG) Test System
|
||
Completed |
NCT06228131 -
Detection of hCG in Early Pregnancy Clinical Samples
|
||
Active, not recruiting |
NCT04388605 -
Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic
|
||
Completed |
NCT00340782 -
Influence of Social and Environmental Factors on Women's Reproductive Function in a Maya Community of Guatemala
|
N/A |